Enhabit, Inc. $EHAB Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its holdings in shares of Enhabit, Inc. (NYSE:EHAB) by 4.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 77,070 shares of the company’s stock after selling 3,690 shares during the period. Rhumbline Advisers owned 0.15% of Enhabit worth $677,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Enhabit by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,565 shares of the company’s stock worth $223,000 after buying an additional 1,216 shares during the last quarter. Mackenzie Financial Corp raised its position in Enhabit by 12.1% during the 1st quarter. Mackenzie Financial Corp now owns 14,468 shares of the company’s stock worth $127,000 after buying an additional 1,564 shares during the last quarter. Magnetar Financial LLC raised its position in Enhabit by 10.4% during the 1st quarter. Magnetar Financial LLC now owns 24,168 shares of the company’s stock worth $212,000 after buying an additional 2,281 shares during the last quarter. GAMMA Investing LLC raised its position in Enhabit by 295.2% during the 1st quarter. GAMMA Investing LLC now owns 3,533 shares of the company’s stock worth $31,000 after buying an additional 2,639 shares during the last quarter. Finally, Versor Investments LP raised its position in Enhabit by 10.7% during the 1st quarter. Versor Investments LP now owns 32,000 shares of the company’s stock worth $281,000 after buying an additional 3,100 shares during the last quarter.

Insider Activity

In related news, CFO Ryan Solomon bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $7.64 per share, with a total value of $76,400.00. Following the completion of the transaction, the chief financial officer owned 193,468 shares of the company’s stock, valued at approximately $1,478,095.52. The trade was a 5.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 3.40% of the company’s stock.

Enhabit Price Performance

Enhabit stock opened at $8.19 on Monday. Enhabit, Inc. has a 12-month low of $6.47 and a 12-month high of $10.90. The stock has a market capitalization of $415.15 million, a P/E ratio of -3.07 and a beta of 1.69. The firm’s 50-day moving average is $7.45 and its two-hundred day moving average is $8.43. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.57 and a quick ratio of 1.57.

Enhabit (NYSE:EHAB) last released its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.03. Enhabit had a negative net margin of 12.84% and a positive return on equity of 2.72%. The business had revenue of $266.10 million for the quarter, compared to analysts’ expectations of $263.39 million. Equities analysts predict that Enhabit, Inc. will post 0.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, UBS Group cut their price objective on shares of Enhabit from $10.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.67.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.